A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

Trial Profile

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Glufosfamide (Primary) ; Fluorouracil
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eleison Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 23 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2018.
    • 05 May 2016 According to an Eleison Pharmaceuticals media release, the China Food and Drug Administration (CFDA) has approved enrollment of patients in China under this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top